Amgen to pay $762 million settlement over drug marketing

NEW YORK — Amgen pleaded guilty in a New York federal court Tuesday for improper marketing practices involving its once top-selling Aranesp anemia drug, and prosecutors said the company has agreed to pay $762 million in a civil settlement and criminal fines.

The world’s largest biotechnology company had set aside funds it expected to have to pay as a result of federal and state investigations, as well as nearly a dozen civil whistleblower lawsuits.

More business news

Consumers could face big changes from net neutrality rules

Consumers could face big changes from net neutrality rules

New rules proposed by the government could change how consumers experience media online.

Regulators who scrapped a review of lenders questioned

Regulators who scrapped a review of lenders questioned

Consultants hired to review mortgage servicers were paid $1.9 billion, leading officials to close the inquiry.

Low-level federal judges raising the bar for digital evidence

Low-level federal judges raising the bar for digital evidence

Some magistrate judges say sweeping requests violate constitutional protections.

More business news

Federal prosecutors said in court that the company had agreed to pay $612 million in a civil settlement, a $14 million criminal forfeiture payment and a $136 million criminal fine.

Amgen entered the guilty plea to one misdemeanor count. Acting U.S. Attorney Marshall Miller confirmed that under the agreement Amgen will not lose any federal business or contracts. Exclusion from federal programs, such as Medicare, could have crippled its business.

Aranesp, primarily used to treat anemia in cancer patients undergoing chemotherapy, remains one of Amgen’s largest drugs with sales of $2.3 billion in 2011.

Amgen was accused of promoting Aranesp for anemia caused by cancer, for which it was not approved, rather than to combat anemia as a side effect of chemotherapy treatments. The company also was accused of pushing higher doses and more convenient treatment schedules than what was approved in the drug’s label for cancer and chronic kidney disease patients.

The government said the illegal practices were undertaken in part to help Amgen take market share from Johnson & Johnson’s similar anemia drug Procrit.

— Reuters

 
Read what others are saying